

SHARPS COMPLIANCE CORP
Form 10QSB
February 11, 2008

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2007

TRANSITION REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission File Number: 0-22390

SHARPS COMPLIANCE CORP.

(Exact name of small business issuer as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

74-2657168
(I.R.S. Employer
Identification No.)

9220 Kirby Drive, Suite 500, Houston, Texas
(Address of principal executive offices)

77054
(Zip Code)

(713) 432-0300
(Issuer's telephone number)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

Edgar Filing: SHARPS COMPLIANCE CORP - Form 10QSB

12,676,913 shares of Common Stock, \$0.01 par value as of February 6, 2008.

Transitional Small Business Disclosure Format (check one): Yes No

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

INDEX

		PAGE
PART I	FINANCIAL INFORMATION	
Item 1.	Financial Statements	
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Income for the three months ended December 31, 2007 and 2006	4
	Condensed Consolidated Statements of Income for the six months ended December 31, 2007 and 2006	5
	Condensed Consolidated Statements of Cash Flows	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis or Plan of Operation	10
Item 3.	Controls and Procedures	17
PART II	OTHER INFORMATION	
Item 1.	Legal Proceedings	18
Item 4.	Submission of Matters to a Vote of Security Holders	18
Item 6.	Exhibits	18
SIGNATURES		19

PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31,	June 30,
	2007	2007
	(Unaudited)	
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 2,673,970	\$ 2,134,152
Restricted cash	10,010	10,010
Accounts receivable, net of allowance for doubtful accounts of \$15,679 and \$15,793, respectively	1,395,943	1,330,731
Inventory	538,283	364,005
Prepaid and other assets	201,405	186,101
TOTAL CURRENT ASSETS	4,819,611	4,024,999
PROPERTY AND EQUIPMENT , net of accumulated depreciation of \$803,515 and \$878,248, respectively	743,436	590,567
INTANGIBLE ASSETS , net of accumulated amortization of \$128,418 and \$120,327, respectively	116,376	75,002
TOTAL ASSETS	\$ 5,679,423	\$ 4,690,568
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable	\$ 857,188	\$ 557,302
Accrued liabilities	320,299	613,851
Deferred revenue	1,008,108	883,678
Current maturities of capital lease obligations	-	1,809
TOTAL CURRENT LIABILITIES	2,185,595	2,056,640
LONG-TERM DEFERRED REVENUE	451,231	392,803
RENT ABATEMENT	70,500	72,000
TOTAL LIABILITIES	2,707,326	2,521,443
COMMITMENTS	-	-
STOCKHOLDERS' EQUITY		
Common stock, \$0.01 par value per share; 20,000,000 shares authorized; 12,185,183 and 11,998,453 shares issued and outstanding, respectively	121,852	119,985
Additional paid-in capital	8,775,918	8,596,321
Accumulated deficit	(5,925,673)	(6,547,181)
TOTAL STOCKHOLDERS' EQUITY	2,972,097	2,169,125
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 5,679,423	\$ 4,690,568

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME

	For the Three Months Ended December 31,	
	2007	2006
	(Unaudited)	
REVENUES		
Product	\$ 3,642,065	\$ 3,094,945
Environmental services	108,737	86,832
TOTAL REVENUES	3,750,802	3,181,777
COSTS AND EXPENSES		
Cost of revenues	2,145,468	1,819,800
Selling, general and administrative	1,185,046	924,122
Depreciation and amortization	65,920	45,477
TOTAL COSTS AND EXPENSES	3,396,434	2,789,399
OPERATING INCOME	354,368	392,378
OTHER INCOME (EXPENSE)		
Interest income	26,100	7,919
Interest expense	(6)	(2,269)
Other income	-	32,500
TOTAL OTHER INCOME	26,096	38,150
INCOME BEFORE INCOME TAXES	380,462	430,528
INCOME TAXES	(558)	(9,332)
NET INCOME	\$ 379,904	\$ 421,196
NET INCOME PER COMMON SHARE		
Basic	\$.03	\$.04
Diluted	\$.03	\$.04
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME PER COMMON SHARE:		
Basic	12,157,441	10,664,557
Diluted	13,494,251	11,576,162

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME

	For the Six Months Ended December 31,	
	2007	2006
	(Unaudited)	
REVENUES		
Product	\$ 6,931,568	\$ 6,016,243
Environmental services	210,346	156,418
TOTAL REVENUES	7,141,914	6,172,661
COSTS AND EXPENSES		
Cost of revenues	4,103,203	3,513,388
Selling, general and administrative	2,340,427	1,878,545
Depreciation and amortization	123,617	89,689
TOTAL COSTS AND EXPENSES	6,567,247	5,481,622
OPERATING INCOME	574,667	691,039
OTHER INCOME (EXPENSE)		
Interest income	52,440	11,468
Interest expense	(44)	(4,176)
Other Income	-	32,500
TOTAL OTHER INCOME	52,396	39,792
INCOME BEFORE INCOME TAXES	627,063	730,831
INCOME TAXES	(5,555)	(18,046)
NET INCOME	\$ 621,508	\$ 712,785
NET INCOME PER COMMON SHARE		
Basic	\$.05	\$.07
Diluted	\$.05	\$.06
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME PER COMMON SHARE:		
Basic	12,109,845	10,608,314
Diluted	13,514,774	11,275,236

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Six Months Ended December	
	31,	
	2007	2006
	(Unaudited)	
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	\$ 621,508	\$ 712,785
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	123,617	89,689
Stock based compensation expense	20,438	-
Excess tax benefits from stock-based award activity	(7,986)	-
Changes in operating assets and liabilities:		
Increase in accounts receivable	(65,212)	(509,344)
(Increase) decrease in inventory	(174,278)	29,348
Increase in prepaid and other assets	(15,304)	(57,246)
Increase in accounts payable and accrued liabilities	12,820	173,760
Increase in deferred revenue	182,858	118,423
NET CASH PROVIDED BY OPERATING ACTIVITIES	698,461	557,415
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property and equipment	(268,395)	(63,429)
Additions to intangible assets	(49,465)	(1,069)
NET CASH USED IN INVESTING ACTIVITIES	(317,860)	(64,498)
CASH FLOWS FROM FINANCING ACTIVITIES		
Payments on capital lease obligations	(1,809)	(27,163)
Excess tax benefits from stock-based award activity	7,986	-
Proceeds from exercise of stock options	153,040	120,640
NET CASH PROVIDED BY FINANCING ACTIVITIES	159,217	93,477
NET INCREASE IN CASH AND CASH EQUIVALENTS	539,818	586,394
CASH AND CASH EQUIVALENTS, beginning of period	2,134,152	296,959
CASH AND CASH EQUIVALENTS, end of period	\$ 2,673,970	\$ 883,353
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		
Cash paid for interest	\$ 44	\$ 4,176

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 - ORGANIZATION AND BACKGROUND

The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.) and Sharps Safety, Inc. (collectively, “Sharps” or the “Company”). All significant intercompany accounts and transactions have been eliminated upon consolidation.

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-QSB and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of December 31, 2007 and the results of its operations and cash flows for the three and six months ended December 31, 2007 and 2006. The results of operations for the three and six months ended December 31, 2007, are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2008. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-KSB for the year ended June 30, 2007.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

REVENUE RECOGNITION

The Company complies with the Securities and Exchange Commission’s (“SEC”) Staff Accounting Bulletin (“SAB”) No. 101, “Revenue Recognition”, which provides guidance related to revenue recognition based on interpretations and practices followed by the SEC. Under SAB No. 101, certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Disposal by Mail Systems, referred to as “Mailback” and Sharps Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements as follows: (1) the sale of the container system, (2) the transportation of the container system and (3) the treatment and disposal (incineration) of the container system. The individual fair value of the transportation and incineration services are determined by the sales price of the service offered by third parties, with the fair value of the container being the residual value. Revenue for the sale of the container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue on Mailbacks is recognized when the customer returns the mailback container system and the container has been received at the Company’s treatment facility. The Mailback container system is mailed to the incineration facility using the United States Postal Service (“USPS”) or United Parcel Service (“UPS”). Incineration revenue is recognized upon the destruction and certification of destruction having been prepared on the container. Since the transportation element and the incineration elements are undelivered services at the point of initial sale of the container, the Mailback revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned. Accordingly, a portion of the transportation and incineration elements is recognized at the point of sale.

NOTE 4 - RECENTLY ISSUED ACCOUNTING STANDARDS

In June 2006, the FASB issued Interpretation No. 48 ("FIN 48"), Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, to clarify certain aspects of accounting for uncertain tax position, including issues related to the recognition and measurement of those tax positions. The Company adopted the provisions of FIN 48 as of July 1, 2007. The adoption of FIN 48 did not have a material effect on the Company's consolidated financial statements. The Company classifies interest and penalties associated with the payment of income taxes in the Other Income (Expense) section of its consolidated statement of operations. Tax return filings which are subject to review by local tax authorities by major jurisdiction are as follows:

· United States - fiscal years ended June 2004, 2005, 2006 and 2007

7

State of Texas - fiscal years ended June 2004, 2005, 2006 and 2007

In September 2006, the FASB issued Statement No. 157, "Fair Value Measurements." SFAS 157 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company does not expect the new standard to have a material impact on its financial position and results of operations.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities — including an Amendment of FASB Statement No. 115." This statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value and establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provisions of SFAS No. 157. The Company expects to adopt SFAS 159 beginning July 1, 2008. The Company is currently evaluating the impact that this pronouncement may have on our consolidated financial statements.

NOTE 5 - INCOME TAXES

During the three and six months ended December 31, 2007 the Company recorded a provision of \$558 and \$5,555 for estimated income taxes. During the three and six months ended December 31, 2006 the Company recorded a provision of \$9,332 and \$18,046 for estimated incomes taxes. For federal income tax purposes the Company is in an Alternative Minimum Tax ("AMT") situation. During the three months ended December 31, 2007 the Company recorded a reduction to income taxes of \$21,180 for prior year tax estimates to the tax return. The Company expects to utilize its net operating loss carry forwards to offset any ordinary taxable income for the year ending June 30, 2008.

NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

Effective February 5, 2007, the Company entered into an Amended Credit Agreement with JPMorgan Chase Bank, N.A. ("Credit Agreement") which provides for a \$2.5 million Line of Credit Facility the proceeds of which may be utilized for, (i) working capital, (ii) letters of credit (up to \$200,000), (iii) acquisitions (up to \$500,000) and (iv) general corporate purposes. Indebtedness under the Credit Agreement is secured by substantially all of the Company's assets. Borrowings bear interest at a fluctuating rate per annum equal to either, (i) prime rate or (ii) LIBOR plus a margin of 2.75%. Any outstanding revolving loans, and accrued and unpaid interest, will be due and payable on March 27, 2009, the maturity date of the facility. The aggregate principal amount of advances outstanding at any time under the Facility shall not exceed the Borrowing Base which is equal to, (i) 80% of Eligible Accounts Receivable (as defined) plus (ii) 50% of Eligible Inventory (as defined). The Credit Agreement contains affirmative and negative covenants that, among other items, require the Company to maintain a specified tangible net worth and fixed charge coverage ratio. The Credit Agreement also contains customary events of default. Upon the occurrence of an event of default that remains uncured after any applicable cure period, the lenders' commitment to make further loans may terminate and the Borrower may be required to make immediate repayment of all indebtedness to the lenders. The lender would also be entitled to pursue other remedies against the Company and the collateral. As of December 31, 2007, there were no borrowings under this Line Of Credit Facility and the Company was in compliance with all loan covenants. Under the Credit Agreement, and based upon the Company's December 31, 2007 level of accounts receivable and inventory, the amount available to borrow at quarter end was \$1.5 million.

NOTE 7 - STOCK-BASED COMPENSATION

In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards (“SFAS”) No. 123 (revised 2004), *Share-Based Payment* (“SFAS 123R”) that addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for equity instruments of the enterprise or liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments. SFAS 123R eliminates the ability to account for share-based compensation transactions using the intrinsic value method under Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees* (“APB 25”), and generally requires instead that such transactions be accounted for using a fair-value-based method. We adopted SFAS 123R beginning July 1, 2006. There is no compensation expense related to the unvested portion of stock options granted prior to July 1, 2006 since the Company’s Board of Directors approved, in June 2006, the acceleration of the vesting of all unvested stock options previously awarded.

SFAS 123R requires the use of a valuation model to calculate the fair value of stock-based awards. The Company has elected to use the Black-Scholes-Merton (“BSM”) pricing model to determine the fair value of stock- options on the dates of grant, consistent with that used for pro forma disclosures under SFAS No. 123, *Accounting for Stock-Based Compensation*. Restricted Stock Units (“RSUs”) are measured based on the fair market values of the underlying stock on the dates of grant. The Company first awarded RSUs on July 2, 2007 (49,500 units).

The Company elected the modified prospective transition method as permitted by SFAS 123R, and accordingly, prior periods have not been restated to reflect the impact of SFAS 123R. Under this method, the Company is required to recognize stock-based compensation for all new and unvested stock-based awards that are ultimately expected to vest as the requisite service is rendered beginning July 1, 2006. Stock-based compensation is measured based on the fair values of all stock-based awards on the dates of grant.

For the three and six months ended December 31, 2007, the Company recognized stock-based compensation expense of (\$9,022) and \$20,438, respectively, which is included in the line item “selling, general and administrative expenses” of the Condensed Consolidated Statement of Income. There was no stock-based compensation expense recognized for the period ended December 31, 2006.

NOTE 8 - EARNINGS PER SHARE

Earnings per share are measured at two levels: basic per share and diluted per share. Basic per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method. The following information is necessary to calculate earnings per share for the periods presented:

	Six Months Ended December 31,	
	2007	2006
	(Unaudited)	
Net income, as reported	\$ 621,508	\$ 712,785
Weighted average common shares outstanding	12,109,845	10,608,314
Effect of Dilutive stock options	1,404,929	666,922
Weighted average diluted common shares outstanding	13,514,774	11,275,236
Net income per common share		
Basic	\$ 0.05	\$ 0.07
Diluted	\$ 0.05	\$ 0.06
Employee stock options excluded from computation of diluted income per share amounts because their effect would be anti-dilutive	75,000	-

NOTE 9 - STOCK TRANSACTIONS

During the quarter ended December 31, 2007, stock options to purchase 30,000 of common shares were exercised. Total proceeds to the Company were \$30,800 (average price of \$1.03 per share). During the quarter ended December 31, 2006 stock options to purchase 125,988 of common shares were exercised. Total proceeds to the Company were \$102,790 (average price of \$0.82 per share).

During the six months ended December 31, 2007, stock options to purchase 186,730 shares of common stock were exercised. Total proceeds to the Company were \$153,040 (average price of \$.82 per share). During the six months ended December 31, 2006, stock options to purchase 160,988 were exercised. Total proceeds to the company were \$120,640 (average price of \$0.75 per share).

During the month of January 2008, stock options to purchase 305,000 of common shares were exercised. Total proceeds to the Company were \$342,250 (average price of \$1.12 per share).

NOTE 10 - SUBSEQUENT EVENT

The Company recently announced the purchase of its previously leased disposal facility in Carthage, Texas. The purchase includes an incinerator with a maximum capacity of thirty (30) tons per day, a 12,000 square foot building and 4.5 acres of land.

Additionally, the Company has executed a purchase order for a state-of-the-art autoclave system and technology capable of treating up to seven (7) tons per day of medical waste at the same facility. Autoclaving is a process that treats medical waste with steam at high temperature and pressure to kill pathogens.

The total cost of the incineration facility purchase, addition of the autoclave technology and other planned improvements at the Carthage, Texas facility is estimated to be approximately \$900,000 and expected to be incurred in the third and fourth quarters of fiscal year 2008.

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-QSB contains certain forward-looking statements and information relating to Sharps that are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. When used in this report, the words "anticipate," "believe," "estimate" and "intend" and words or phrases of similar import, as they relate to Sharps or Company management, are intended to identify forward-looking statements. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein. Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected or intended. The Company does not intend to update these forward-looking statements.

GENERAL

Sharps is a leading developer and manufacturer of cost effective solutions for improving safety, efficiency and costs related to the proper disposal of medical waste by industry and consumers. Sharps primary markets include healthcare, retail, agriculture, hospitality, professional, industrial, commercial, governmental and pharmaceutical. The Company's products and services represent solutions for industries and consumers dealing with the complexity of managing regulatory compliance, environmental sensitivity, employee and customer safety, corporate risk and operating costs related to medical waste disposal. Sharps is a leading proponent and participant in the development of public awareness and solutions for the safe disposal of needles, syringes and other sharps in the community setting.

The Company's primary products include Sharps Disposal by Mail System®, Pitch-It™ IV Poles, Trip LesSystem®, Sharps Pump Return Box, Sharps Enteral Pump Return Box, Sharps Secure®, Sharps SureTemp Tote®, IsoWash® Linen Recovery System, Biohazard Spill Clean-Up Kit and Disposal System, Sharps e-Tools, Sharps Environmental Services and Sharps Consulting. Some products and services facilitate compliance with state and federal regulations by tracking, incinerating and documenting the disposal of medical waste. Additionally, some products and services facilitate compliance with educational and training requirements required by federal, state, and local regulatory agencies.

RESULTS OF OPERATIONS

The following analyzes changes in the consolidated operating results and financial condition of the Company during the three and six months ended December 31, 2007 and 2006.

10

The following table sets forth, for the periods indicated, certain items from the Company's Condensed Consolidated Statements of Income, expressed as a percentage of revenue (unaudited):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2007	2006	2007	2006
Net revenues	100%	100%	100%	100%
Costs and expenses:				
Cost of revenues	(57%)	(57%)	(57%)	(57%)
Selling, general and administrative	(32%)	(30%)	(33%)	(30%)
Depreciation and amortization	(2%)	(1%)	(2%)	(1%)
Total operating expenses	(91%)	(88%)	(92%)	(88%)
Income from operations	9%	12%	8%	11%
Total other income (expense)	1%	1%	1%	1%
Net income	10%	13%	9%	12%

THREE MONTHS ENDED DECEMBER 31, 2007 AS COMPARED TO THREE MONTHS ENDED DECEMBER 31, 2006

Total revenues for the three months ended December 31, 2007 of \$3,750,802 increased by \$569,025, or 17.9%, over the total revenues for the three months ended December 31, 2006 of \$3,181,777. Billings by market are as follows:

	Three Months Ended December 31,		
	2007 (Unaudited)	2006 (Unaudited)	Variance (Unaudited)
Billings by Market:			
Health Care	\$ 1,933,695	\$ 1,899,277	\$ 34,418
Pharmaceutical	491,157	41,770	449,387
Retail	315,115	238,850	76,265
Hospitality	306,779	191,584	115,195
Agriculture	173,694	221,214	(47,520)
Professional	168,317	138,713	29,604
Commercial/Industrial	160,137	206,220	(46,083)
Protec	116,253	100,944	15,309
Government	85,090	51,308	33,782
Other	35,072	59,236	(24,164)
Subtotal	3,785,309	3,149,116	636,193
GAAP Adjustment*	(34,507)	32,661	(67,168)
Revenue Reported	\$ 3,750,802	\$ 3,181,777	\$ 569,025

*Represents the net impact of the revenue recognition adjustment required to arrive at reported GAAP revenue. Customer billings includes all invoiced amounts associated with products shipped during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with product returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company's balance sheet as deferred revenue. See Note 3 "Revenue Recognition" in Part I, "Notes to Consolidated Financial Statements".

The increase in revenues is primarily attributable to increased billings in the Pharmaceutical (\$449,387), Hospitality (\$115,195), Retail (\$76,265), Health Care (\$34,418), Government (\$33,782) and Professional (\$29,604) markets. These increases were partially offset by decreased billings in the Agriculture (\$47,520) and Commercial/Industrial

(\$46,083) markets. The increase in the billings in the Pharmaceutical market includes \$429 thousand in billings to a top ten pharmaceutical manufacturing customer under the previously announced \$1.4 million purchase order. The pharmaceutical market also includes \$62 thousand in billings to two major pharmaceutical manufacturers for the Sharps Disposal By Mail System ® and the Sharps Transport Tube™. The increase in the billings in the Retail market is a result of the use of the Company's Sharps Disposal By Mail System ® products in grocery stores and retail pharmacies to properly dispose of syringes utilized to administer flu and other inoculations. The increase in the Hospitality market reflects increased demand of the Sharps Disposal by Mail System® and Biohazard Spill Clean-Up Kit products by hotels, restaurants and assisted living facilities. The increase in the Health Care market billings is a result of the growing number of patients in the health care industry and the increased utilization of the Sharps Disposal by Mail System® by home care branches. The decrease in the Agriculture market is primarily attributable to decreased demand of the Sharps Disposal by Mail System by a customer who provides the product to facilitate the injection of dairy cattle due to growing public concern over the use of hormones. The decrease in the Commercial/Industrial market is primarily attributable to the prior fiscal year fulfillment of an order for Sharps Secure® for a large public real estate company who placed the units in malls across the country last year.

Cost of revenues for the three months ended December 31, 2007 of \$2,145,468 was 57% of revenues, which is consistent with the corresponding period of the prior year.

Selling, general and administrative (“S, G & A”) expenses for the three months ended December 31, 2007 of \$1,185,046, increased by \$260,924, or 28%, over the S, G & A expenses for the three months ended December 31, 2006. The increase in S, G & A expense is primarily due to higher, (i) compensation expense (\$90,616) (ii) sales and marketing related expenses including sales-related travel (\$43,368), (iii) professional fees (\$36,000), (iv) office lease expense (\$34,020), and (v) investor relations expenses (\$31,785). The increase in compensation expense was due to the hiring of a full time director of information/ technology (previously an outside services expense), and increased sales and sales support staff. The increase in travel is directly related to the Company’s increased sales and marketing efforts. The professional fees increase is primarily for consulting work related to major sales initiatives. The investor relations expense increased due to the hiring of an investor relation firm in January of 2007.

The Company generated operating income of \$354,368 for the three months ended December 31, 2007 compared to \$392,378 for the three months ended December 31, 2006. The decrease in operating income is a result of the increase in S, G & A.

Interest income increased from \$7,919 to \$26,100 as a result of higher cash balances for the respective periods. Other income included in the Company’s statement of income for the prior fiscal year period reflects the net proceeds of \$32,500 from partial recovery and settlement of a lawsuit.

The Company generated income before tax of \$380,462 for the three months ended December 31, 2007 versus a pre-tax income of \$430,528 for the three months ended December 31, 2006. The decrease in the earnings for the period is due primarily to the increased S, G & A for the three months ended December 31, 2007 versus 2006.

The Company reported earnings per share of \$0.03 for the three months ended December 31, 2007 versus earnings per share of \$0.04 for the three months ended December 31, 2006. The reduction in diluted earnings per share is a result of, (i) decreased net income for the current fiscal year period and (ii) the adverse effect to earnings per share computation of a 1.9 million, or 17%, increase in the diluted shares outstanding (resulting from stock options exercised and a higher stock price (treasury stock method)).

SIX MONTHS ENDED DECEMBER 31, 2007 AS COMPARED TO SIX MONTHS ENDED DECEMBER 31, 2006

Total revenues for the six months ended December 31, 2007 of \$7,141,914 increased by \$969,253, or 15.7%, over the total revenues for the six months ended December 31, 2006 of \$6,172,661. Billings by market are as follows:

	Six Months Ended December 31,		
	2007	2006	Variance
	(Unaudited)	(Unaudited)	(Unaudited)
Billings by Market:			
Health Care	\$ 3,852,959	\$ 3,716,863	\$ 136,096
Retail	1,000,551	871,853	128,698
Hospitality	670,014	307,917	362,097
Pharmaceutical	498,342	56,933	441,409
Professional	339,501	275,052	64,449
Commercial/Industrial	276,246	316,854	(40,608)
Agriculture	266,998	341,905	(74,907)
Protec	241,523	218,073	23,450
Government	141,151	105,165	35,986

Edgar Filing: SHARPS COMPLIANCE CORP - Form 10QSB

Other	84,276	80,830	3,446
Subtotal	7,371,561	6,291,445	1,080,116
GAAP Adjustment*	(229,647)	(118,784)	(110,863)
Revenue Reported	\$ 7,141,914	\$ 6,172,661	\$ 969,253

*Represents the net impact of the revenue recognition adjustment required to arrive at reported GAAP revenue. Customer billings includes all invoiced amounts associated with products shipped during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with product returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company's balance sheet as deferred revenue. See Note 3 "Revenue Recognition" in Part I, "Notes to Consolidated Financial Statements".

The increase in revenues is primarily attributable to increased billings in the Pharmaceutical (\$441,409), Hospitality (\$362,097), Health Care (\$136,096), Retail (\$128,698), Professional (\$64,449) and Government (\$35,986) markets. These increases were partially offset by decreased billings in the Agriculture (\$74,907) and Commercial/Industrial (\$40,608) markets. The increase in the billings in the Pharmaceutical market includes \$429 thousand in billings to a top ten pharmaceutical manufacturing customer under the previously announced \$1.4 million purchase order. The pharmaceutical market also includes \$62 thousand in billings to two major pharmaceutical manufacturers for the Sharps Disposal By Mail System® and the Sharps Transport Tube™. The increase in the Hospitality market reflects increased demand of the Sharps Disposal by Mail System® and Biohazard Spill Clean-Up Kit products by hotels, restaurants and assisted living facilities. The increase in the Health Care market billings is a result of the growing number of patients in the health care industry and the increased utilization of the Sharps Disposal by Mail System® by home care branches. The increase in the billings in the Retail market is a result of the use of the Company's Sharps Disposal By Mail System® products in grocery stores and retail pharmacies to properly dispose of syringes utilized to administer flu and other inoculations. The decrease in the Agriculture market is primarily attributable to decreased demand of the Sharps Disposal by Mail System by a customer who provides the product to facilitate the injection of dairy cattle due to growing public concern over the use of hormones. The decrease in the Commercial/Industrial market is primarily attributable to the prior fiscal year fulfillment of an order for Sharps Secure® for a large public real estate company who placed the units in malls across the country last year.

Cost of revenues for the six months ended December 31, 2007 of \$4,103,203 was 57% of revenues, which is consistent with the corresponding period of the prior year.

Selling, general and administrative ("S, G & A") expenses for the six months ended December 31, 2007 of \$2,340,427, increased by \$461,882, or 25%, over the S, G & A expenses for the six months ended December 31, 2006. The increase in S, G & A expense is primarily due to higher, (i) compensation expense (\$148,431) (ii) office lease expense (\$68,794), (iii) sales and marketing related expenses (\$62,337), (iv) investor relations expenses (\$45,307) (v) non-cash stock-based compensation expense (\$20,438), (vi) the cash portion of Board of Director compensation expense (\$40,000) (vii) sales-related professional fees (\$26,000). The increase in compensation expense was due to the hiring of a full time director of information/ technology (previously an outside services expense), and increased sales and sales support staff. The increase in travel is directly related to the Company's increased sales and marketing efforts. The investor relations expense increased due to the hiring of an investor relation firm in January of 2007. The professional fees increase is primarily for consulting work related to major sales initiatives.

The Company generated operating income of \$574,667 for the six months ended December 31, 2007 compared to \$691,039 for the six months ended December 31, 2006. The decrease in operating income is a result of the increase in S, G & A.

Other income included in the Company's statement of income for the six months ended December 31, 2007 of \$52,396 reflects an increase interest income of \$40,972 and decrease in interest expense of \$4,132. The increase in interest income is a result of higher cash balances during the respective periods. The reduction in interest expense is due to the lower corresponding capital lease balances. Other income also reflects the net proceeds of \$32,500 from partial recovery and settlement of litigation.

The Company generated income before tax of \$627,063 for the six months ended December 31, 2007 versus a pre-tax income of \$730,831 for the six months ended December 31, 2006. The reduction in net income is due primarily to the increase in S, G & A for the respective periods.

The Company reported diluted earnings per share of \$0.05 for the six months ended December 31, 2007 versus diluted earnings per share of \$0.06 for the six months ended December 31, 2006. The reduction in diluted earnings per share is a result of, (i) decreased net income for the current fiscal year period and (ii) the adverse effect to earnings per share computation of a 2.2 million, or 20%, increase in the diluted shares outstanding (resulting from stock options

exercised and a higher stock price (treasury stock method)).

PROSPECTS FOR THE FUTURE

The Company continues to take advantage of the many opportunities in the markets served as communities, consumers and industries become more aware of the proper disposal of medical sharps (syringes, lancets, etc.). This education process was enhanced in March 2004 when the U. S. Environmental Protection Agency (“EPA”) issued its new guidelines for the proper disposal of medical sharps (see www.epa.gov/epaoswer/other/medical/sharps.htm). Additionally, in July 2006 both the states of California and Massachusetts passed legislation designed to mandate appropriate disposal of sharps waste necessary to protect the general public and workers from potential exposure to contagious diseases and health and safety risks. In August 2007, the U.S. House of Representatives and U.S. Senate introduced bills 3251 and 1909, respectively, which would provide for Medicare reimbursement, under part D, for the safe and effective disposal of used needles and syringes. Among the methods of disposal recommended as part of the above noted regulatory actions are mail-back programs such as those marketed by the Company. The Company estimates that there are an estimated 2 billion used syringes disposed of in the United States outside of the hospital setting. Additionally, the Company estimates that it would require 30 - 40 million Sharps Disposal by Mail System® products to properly dispose of all such syringes, which would equate to a \$1 billion small quantity generator market opportunity. Based upon the current level of sales, the Company estimates that this \$1 billion market has only been penetrated by approximately 1% or less.

The Company continues to develop new products for all of its product lines. The Company believes its future growth will be driven by, among other items, (i) the positive impact and awareness created by the above noted regulatory actions as well as additional potential future legislation, (ii) the effects of the Company's extensive direct marketing efforts and (iii) continued brand awareness of the Sharps Disposal By Mail Systems(s). The result of these direct marketing efforts was recognized with the receipt of the first major pharmaceutical manufacturer order, valued at \$1.4 million, from a recognized and leading pharmaceutical manufacturer. The initial \$0.45 million order was billed during March 2007 with fulfillment services to patients beginning in May 2007. In December 2007, an additional \$400 thousand in product was shipped, with the remaining approximate \$400 thousand to be shipped in February 2008, achieving virtually the entire contract value of \$1.4 million.

Looking forward, the Company is targeting customer billings of \$15 million to \$16 million for fiscal year 2008 led by expected growth in the pharmaceutical, retail, hospitality and professional markets. The Company anticipates gross margin to remain in the low to mid-40% range for the fiscal year 2008 and S, G & A for the fiscal year 2008 of \$4.5 to \$4.6 million, exclusive of any non-cash stock-based compensation expense (SFAS 123R). The increased investment in S, G & A over the prior year is primarily a result of increased sales and marketing expenses incurred in order to address what the Company believes to be significant sales opportunities in multiple markets. The Company believes the increased sales and marketing spending to be prudent as it is designed to accelerate revenue growth and fully capitalize on what it believes to be a billion dollar emerging market.

Demand for the Company's primary product, the Sharps Disposal by Mail System®, which facilitates the proper and cost-effective disposal of medical waste including hypodermic needles, lancets and other devices or objects used to puncture or lacerate the skin (referred to as "sharps"), has been growing rapidly in the small quantity generator sector because of its mail-back convenience and unique data tracking feature. In addition, targeted opportunities continue to expand as a result of the growing awareness of the need to properly handle sharps medical waste for safety and environmental concerns, the expanding need for self-injectable medications and the changing paradigm in the health industry.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents increased by \$539,818 to \$2,673,970 at December 31, 2007 from \$2,134,152 at June 30, 2007. The increase in cash and cash equivalents is primarily a result of cash generated from operations of \$706,447 plus proceeds from the exercise of stock options of \$153,040, partially offset by additions to property and equipment and intangible assets of \$317,860 and payment on capital lease obligations of \$1,809.

Accounts receivable increased by \$65,212 to \$1,395,943 at December 31, 2007 from \$1,330,731 at June 30, 2007. The increase is a direct result of the increase in billings generated by the Company for the quarter ended December 31, 2007 versus the quarter ended June 30, 2007.

Property and equipment increased by \$152,869 to \$743,436 at December 31, 2007 from \$590,567 at June 30, 2007. This increase is attributable to capital expenditures of \$268,395, partially offset by depreciation expense of \$115,526 for the six months ended December 31, 2007. The capital expenditures are attributable to the purchase of, (i) custom software programming of \$111,147, (ii) assembly/warehouse-related equipment \$72,486, (iii) molds, dies and printing plates for production \$49,856 (iv) computer equipment of \$18,193, (v) incinerator facility improvements of \$10,175 and (vi) autoclave permits of \$6,538. The custom software program was incurred to upgrade the Company's financial and operations system and the proprietary Sharps Tracer™ system. The assembly/warehouse-related equipment was related to equipment necessary to accommodate the in-house assembly of the Company's products. The molds and printing plates were procured for development of new product and additional production capacity. The computer equipment was purchased to facilitate the upgrade of outdated equipment. The permits are in preparation for the purchase and installation of autoclave technology at the facility in Carthage Texas.

Stockholder's equity increased by \$802,972 from \$2,169,125 to \$2,972,097. This increase is attributable to (i) net income for the six months ended December 31, 2007 of \$621,508 and (ii) the effect of stock options to purchase 186,730 common stock exercised with proceeds of \$153,040 (average exercise price of \$0.82), (iii) the effect on equity of SFAS 123R expense of \$20,438 and (iv) the excess tax benefits from stock-based award activity of \$7,986.

During the month of January 2008 stock options to purchase 305,000 of common shares were exercised. Total proceeds to the Company were \$342,250 (average price of \$1.12 per share).

Disposal Facility

The Company recently announced the purchase of its previously leased disposal facility in Carthage, Texas. The purchase includes an incinerator with a maximum capacity of thirty (30) tons per day, a 12,000 square foot building and 4.5 acres of land.

Additionally, the Company has executed a purchase order for a state-of-the-art autoclave system and technology capable of treating up to seven (7) tons per day of medical waste at the same facility. Autoclaving is a process that treats medical waste with steam at high temperature and pressure to kill pathogens. An autoclave is environmentally cleaner and is a less costly method of treating most medical waste versus traditional incineration.

With the addition of the autoclave, the Company believes it will own one of only approximately ten (10) permitted commercial disposal facilities in the country capable of treating all types of medical waste.

Sharps is also expanding its ability to dispose of unused medications and expired pharmaceutical waste including controlled substances. The Company is in the process of installing Drug Enforcement Agency (DEA) approved equipment necessary to obtain DEA certification for the disposal of controlled substances.

The total cost of the incineration facility purchase, addition of the autoclave technology and other planned improvements at the Carthage, Texas facility is estimated to be approximately \$900,000 and expected to be incurred in the third and fourth quarters of fiscal year 2008.

New Operating and Accounting System

The Company has recently implemented a project to replace and upgrade its integrated operations and accounting system. The Company's existing system is approximately five (5) years old. The total cost of the project (including software, hardware and implementation fees) is estimated to range from \$225,000 - \$250,000 and is expected to be incurred during the third and fourth quarters of fiscal year 2008. The new system is expected to be launched July 1, 2008.

Management believes that the Company's current cash resources along with its \$2.5 million line of credit will be sufficient to fund operations for the twelve months ending December 31, 2008.

CRITICAL ACCOUNTING ESTIMATES

Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points and can consist of up to three separate elements as follows: (1) the sale of the container system, (2) the transportation of the container system and (3) the treatment and disposal (incineration) of the container system. Since the transportation element and the incineration elements are undelivered services at the point of initial sale of the container, the revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned. Accordingly, a portion of the transportation and incineration elements is recognized at the point of sale.

Governmental Regulation

Operations and Incinerator

Sharps is required to operate within guidelines established by federal, state, and/or local regulatory agencies. Such guidelines have been established to promote occupational safety and health standards and certain standards have been

established in connection with the handling, transportation and disposal of certain types of medical and solid wastes, including mailed sharps. Sharps believes that it is currently in compliance in all material respects with all applicable laws and regulations governing its business. However, in the event additional guidelines are established to more specifically control the business of Sharps, including the environmental services subsidiary, additional expenditures may be required in order for Sharps to be in compliance with such changing regulations. Furthermore, any material relaxation of any existing regulatory requirements governing the transportation and disposal of medical sharps products could result in a reduced demand for Sharps' products and services and could have a material adverse effect on Sharps' revenues and financial condition. The scope and duration of existing and future regulations affecting the medical and solid waste disposal industry cannot be anticipated and are subject to change due to political and economic pressures.

In November 2005, the EPA amended the Clean Air Act which will affect the operations of the leased incineration facility located in Carthage, Texas. The regulation modifies the emission limits and monitoring procedures required to operate an incineration facility. The new rules will necessitate changes to the Company's leased incinerator and pollution control equipment at the facility or require installation of an alternative treatment method to ensure compliance. Such change would require the Company to incur significant capital expenditures in order to meet the requirements of the regulations. The regulation allows a minimum period of three years and a maximum of five years to comply after the date the final rule was published. The Company has studied the amended EPA Clean Air Act and its options, and has decided in the interim to move forward with the process of adding alternative technology, autoclaving, for medical waste disposal with plans to be fully operational in fiscal year 2009 at its current facility in Carthage, Texas. Autoclaving is a process that treats regulated waste with steam at high temperature and pressure to kill pathogens. Combining the autoclaving with a shredding or grinder process allows the waste to be disposed in a landfill operation. The Company believes autoclaving is environmentally cleaner and a less costly method of treating medical waste than incineration. See Disposal Facility section above for further information regarding the purchase of the Carthage, Texas facility and addition of autoclave technology.

Proper Disposal of Medical Sharps

The first significant regulatory development occurred in December 2004 with the improved guidance issued by the Environmental Protection Agency ("EPA") regarding the safe disposal of medical sharps (needles, syringes and lancets). This new guidance is a result of disposal problems created by the estimated 2 billion syringes discarded annually by self-injectors of medicines in homes and non-healthcare commercial facilities. Until December 2004, the EPA guidance has instructed consumers to place used sharps in a household container and to place the container in the household garbage. New guidance posted on the EPA website reflects information about alternative disposal methods including mail-back programs. The improved guidance issued by the EPA is a significant step toward the removal of needles, syringes and other sharps from the solid waste stream, consistent with the current practice in healthcare facilities. The Company's products and services, which are included in the EPA list of recommended solutions, are designed to improve safety, efficiency and patient concerns related to the proper disposal of medical sharps.

The next regulatory development was the enactment of California Senate Bill 1362, "The Safe Needle Disposal Act of 2004." This legislation authorizes California agencies to expand the scope of their existing household hazardous waste plans to provide for the safe disposal of medical sharps including hypodermic needles and syringes. Authorized disposal programs include the mail-back programs currently marketed by the Company.

In July 2006, the State of California passed Senate Bill 1305 ("SB 1305"), an amendment to The Medical Waste Management Act. The new law requires the proper disposal of home-generated sharps waste (syringes, needles, lancets, etc.) and acknowledges mail-back programs as one of the most convenient alternatives for the collection and destruction of home-generated sharps. Effective January 1, 2007 (with enforcement beginning September 1, 2008), SB 1305 addresses the need to meet the changing demands of healthcare provided in alternate sights that currently allows hundreds of millions of home-generated sharps waste to be disposed in solid waste and recycling containers. The new law is designed to ensure appropriate disposal of sharps waste necessary to protect the general public and workers from potential exposure to contagious diseases and health and safety risks.

Also in July 2006, The Massachusetts Legislature enacted Senate Bill 2569 which requires the Massachusetts department of public health, in conjunction with other relevant state and local agencies and government departments, to design, establish and implement a program for the collection and disposal of non-commercially generated, spent hypodermic needles and lancets. Recommended disposal methods include mail-back products approved by the U.S. Postal Service such as the Sharps Disposal By Mail Systems®. The Massachusetts legislation addresses the need for proper disposal of used syringes, needles and lancets outside of the traditional healthcare setting.

In addition to California and Massachusetts, other states are considering similar options.

In August 2007, the U.S. House of Representatives and U.S. Senate introduced bills 3251 and 1909, respectively, which would provide for Medicare reimbursement, under part D, for the safe and effective disposal of used needles and syringes through a sharps-by mail or similar program. This legislation proposes Medicare coverage for the safe needle disposal for approximately 1.3 million insulin-dependent diabetic beneficiaries and is intended to reduce the number of accidental injuries, infections and subsequent costs associated with the improper disposal of approximately 4 million needles generated daily by Medicare covered diabetics. The Company's Sharps Disposal By Mail Systems® is an example of the cost-effective and easy-to-use solution recommended in the legislation.

RECENTLY ISSUED ACCOUNTING STANDARDS

In June 2006, the FASB issued Interpretation No. 48 ("FIN 48"), Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, to clarify certain aspects of accounting for uncertain tax position, including issues related to the recognition and measurement of those tax positions. The Company adopted the provisions of FIN 48 as of July 1, 2007. The adoption of FIN 48 did not have a material effect on the Company's consolidated financial

statements. The Company classifies interest and penalties associated with the payment of income taxes in the Other Income (Expense) section of its consolidated statement of operations. Tax return filings which are subject to review by local tax authorities by major jurisdiction are as follows:

- United States - fiscal years ended June 2004, 2005, 2006 and 2007
- State of Texas - fiscal years ended June 2004, 2005, 2006 and 2007

In September 2006, the FASB issued Statement No. 157, "Fair Value Measurements." SFAS 157 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company does not expect the new standard to have a material impact on its financial position and results of operations.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities — Including an Amendment of FASB Statement No. 115." This statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value and establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provisions of SFAS No. 157. The Company expects to adopt SFAS 159 beginning July 1, 2008. The Company is currently evaluating the impact that this pronouncement may have on our consolidated financial statements.

ITEM 3. CONTROLS AND PROCEDURES

The Company maintains disclosure controls and procedures that are designed to ensure that material information required to be disclosed in the Company's periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. The Company's disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including, its principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

During the quarter the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the chief executive officer and the chief financial officer, of the effectiveness of the design and operation of the disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, the Company's chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures were effective, as of the end of the period covered by this report (December 31, 2007).

During the first six months of the fiscal year 2008, there were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected or are reasonably likely to materially affect internal control over financial reporting.

The certifications required by Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits 31.1 and 31.2, respectively, to this Quarterly Report on Form 10-QSB.

PART II - OTHER INFORMATION**ITEM 1. LEGAL PROCEEDINGS*****Patent Infringement Litigation***

In May 2007, the Company filed patent infringement lawsuits in the United States District Court for the Southern District of Texas in Houston against MediSupply, Inc. (a/k/a or f/k/a Medi-Supply Alliance, LLC and Medi-Supply, Inc. "MediSupply") and Drive Medical Design & Manufacturing ("Drive Medical") for infringement of three U.S. patents. The complaints allege that MediSupply and Drive Medical infringe the patents by making, selling, and offering for sale disposable IV poles which are identical to the Company's Pitch-It™ IV Pole.

On January 2, 2008, the Company announced the settlement of the patent dispute with MediSupply and Drive Medical. In conjunction with the settlement, Drive Medical will be the exclusive manufacturer and Sharps will be the exclusive seller of the Sharps Pitch-It™ IV Poles. Additionally, Drive Medical and MediSupply will no longer sell IV Pole products that infringe upon Sharps' patents. The settlement resolved all issues between the parties related to the patent litigation. As part of the exclusivity agreement, Sharps agreed to a minimum annual purchase commitment of \$600,000 in IV Pole product a year. The Company believes it will purchase more than \$600,000 in IV Pole products from Drive Medical on an annual basis.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On November 15, 2007, the Company held its Annual Meeting of shareholders whereby the following items were voted upon, (i) the election of six directors to hold office until the next annual shareholders meeting, and (ii) other matters that may be presented at the meeting for action.

The following Directors were elected at the meeting, (i) Dr. Burt Kunik, (ii) Ramsay Gillman, (iii) John R. Grow, (iv) Parris H. Holmes, Jr., (v) F. Gardner Parker and (vi) Philip C. Zerrillo.

As of September 27, 2007, the record date of the Annual Meeting, 12,154,101 shares of common stock were outstanding. At the Annual Meeting, holders of 10,131,439 shares of common stock were present in person or represented by proxy. The following sets forth information regarding the results of the voting at the Annual Meeting.

Proposal I - Election of Directors

	Votes in Favor	Votes Withheld
Dr. Burt Kunik	10,120,839	10,600
Ramsay Gillman	10,131,439	-
John R. Grow	10,131,439	-
Parris H. Holmes, Jr.	10,131,439	-
F. Gardner Parker	10,131,439	-
Philip C. Zerrillo	10,131,439	-

ITEM 6. EXHIBITS

(a) Exhibits:

- 31.1 Certification of Chief Executive Officer in Accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)
- 31.2 Certification of Chief Financial Officer in Accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)

32.1 Certification of Chief Executive Officer in Accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

32.2 Certification of Chief Financial Officer in Accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

ITEMS 2, 3, AND 5 ARE NOT APPLICABLE AND HAVE BEEN OMITTED.

18

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.

REGISTRANT:

SHARPS COMPLIANCE CORP.

Dated: February 11, 2008

By: /s/ Dr. Burton J. Kunik

Chairman of the Board of Directors,
Chief Executive Officer and President

Dated: February 11, 2008

By: /s/ David P. Tusa

Executive Vice President,
Chief Financial Officer,
Business Development and
Corporate Secretary